Treatment for Stage I NSCLC Patients Up From 2000 to 2010

Share this content:
Treatment for Stage I NSCLC Patients Up From 2000 to 2010
Treatment for Stage I NSCLC Patients Up From 2000 to 2010

FRIDAY, Oct. 27, 2017 (HealthDay News) -- For patients with stage I non-small-cell lung cancer (NSCLC), the odds of receiving radiation therapy (RT) or surgery increased from 2000 to 2010, with improved survival during the same period, according to a study published online Oct. 26 in the Annals of Thoracic Surgery.

Nirav S. Kapadia, M.D., from Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire, and colleagues conducted a population-based comparative effectiveness study using Surveillance, Epidemiology, and End Results-18 data from 2000 to 2010 for stage I NSCLC patients. A total of 40,589 patients (62 percent) underwent surgery, 10,048 (15 percent) received RT, 2,130 (3 percent) received both surgery and RT, and 11,537 (18 percent) received neither surgery nor RT.

The researchers found that there was an increase annually in the odds of either receiving definitive RT or undergoing surgery relative to the odds of receiving no treatment (odds ratios, 1.04 and 1.05, for RT and surgery, respectively). The proportion of sublobar resections increased steadily among surgical patients, from 12.9 to 17.9 percent. Each year there was a 3.5 percent decrease in the two-year risk of death for all patients (hazard ratio, 0.965), driven mainly by improved survival for surgical and RT patients (annualized hazard ratios, 0.959 and 0.942, respectively).

"Between 2000 and 2010, stage I NSCLC patients were more likely to receive definitive treatment with either surgery or RT, leading to a decline in the number of untreated patients," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell Lymphomas

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell ...

Second study shows benefit in relapsed or refractory B-cell lymphoma, follicular lymphoma

ASH: AAVD Beats ABVD for Advanced Hodgkin's Lymphoma

ASH: A+AVD Beats ABVD for Advanced Hodgkin's Lymphoma

Lower combined risk of progression, death, or noncomplete response with A+AVD

ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia A

ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia ...

Factor VIII gene transfer tied to sustained normalization of factor VIII activity levels

is free, fast, and customized just for you!

Already a member?

Sign In Now »